IL160720A0 - Composition and methods for priming monocytic dendritic cells and t cells for th-1 response - Google Patents

Composition and methods for priming monocytic dendritic cells and t cells for th-1 response

Info

Publication number
IL160720A0
IL160720A0 IL16072002A IL16072002A IL160720A0 IL 160720 A0 IL160720 A0 IL 160720A0 IL 16072002 A IL16072002 A IL 16072002A IL 16072002 A IL16072002 A IL 16072002A IL 160720 A0 IL160720 A0 IL 160720A0
Authority
IL
Israel
Prior art keywords
cells
response
composition
methods
monocytic dendritic
Prior art date
Application number
IL16072002A
Other languages
English (en)
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Publication of IL160720A0 publication Critical patent/IL160720A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
IL16072002A 2001-09-06 2002-09-06 Composition and methods for priming monocytic dendritic cells and t cells for th-1 response IL160720A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31759201P 2001-09-06 2001-09-06
PCT/US2002/028620 WO2003022215A2 (en) 2001-09-06 2002-09-06 Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response

Publications (1)

Publication Number Publication Date
IL160720A0 true IL160720A0 (en) 2004-08-31

Family

ID=32654226

Family Applications (3)

Application Number Title Priority Date Filing Date
IL16072002A IL160720A0 (en) 2001-09-06 2002-09-06 Composition and methods for priming monocytic dendritic cells and t cells for th-1 response
IL160720A IL160720A (en) 2001-09-06 2004-03-03 Compounds and methods for priming monocytic dendritic cells and T cells for the TH – 1 response
IL219266A IL219266A (en) 2001-09-06 2012-04-18 A method for producing a type I training response involving mature dendritic cells

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL160720A IL160720A (en) 2001-09-06 2004-03-03 Compounds and methods for priming monocytic dendritic cells and T cells for the TH – 1 response
IL219266A IL219266A (en) 2001-09-06 2012-04-18 A method for producing a type I training response involving mature dendritic cells

Country Status (18)

Country Link
US (2) US20050059151A1 (zh)
EP (3) EP1441591B1 (zh)
JP (3) JP2005505270A (zh)
KR (3) KR20110081341A (zh)
CN (2) CN102973928B (zh)
AU (1) AU2008221592B2 (zh)
BR (1) BRPI0212545B8 (zh)
CA (1) CA2459713C (zh)
DK (2) DK2322603T3 (zh)
ES (2) ES2766299T3 (zh)
HK (1) HK1079989A1 (zh)
IL (3) IL160720A0 (zh)
MX (1) MXPA04002147A (zh)
NO (2) NO338147B1 (zh)
NZ (1) NZ531530A (zh)
PL (1) PL372098A1 (zh)
PT (2) PT2322603T (zh)
WO (1) WO2003022215A2 (zh)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT412145B (de) * 2002-09-13 2004-10-25 Forsch Krebskranke Kinder Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
US20040057935A1 (en) * 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
ES2354944T3 (es) * 2002-12-06 2011-03-21 Northwest Biotherapeutics, Inc. Administración de células dendríticas maduradas parcialmente in vitro para el tratamiento de tumores.
MXPA05009178A (es) * 2003-02-27 2006-03-08 Northwest Biotherapeutics Inc Generacion de celulas dendriticas a partir de celulas precursoras dendriticas monociticas con gm-csf en ausencia de citocinas adicionales.
EP1484064A1 (en) 2003-06-04 2004-12-08 Gesellschaft für Biotechnologische Forschung Therapeutical composition containing dentritic cells and use thereof
JP2007507543A (ja) * 2003-10-06 2007-03-29 セダーズ−シナイ メディカル センター 樹状細胞治療によって誘導されるｔ細胞アネルギーを予防するためのｃｏｘ−２インヒビターの使用
US7939090B2 (en) * 2003-10-21 2011-05-10 Cedars-Sinai Medical Center System and method for the treatment of cancer, including cancers of the central nervous system
CN1902312B (zh) * 2003-11-04 2011-02-23 株式会社载体研究所 制备导入了基因的树突细胞的方法
KR20070028573A (ko) 2004-06-24 2007-03-12 가부시키가이샤 디나벡크 겐큐쇼 마이너스 가닥 ｒｎａ 바이러스를 포함하는 항암제
AU2006321794A1 (en) * 2005-12-08 2007-06-14 Northwest Biotherapeutics, Inc. Compositions and methods for inducing the activation of immature monocytic dendritic cells
EP1840206A1 (en) * 2006-03-28 2007-10-03 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions for the preparation of mature dendritic cells
EP2084267B1 (en) 2006-09-26 2018-04-11 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8871211B2 (en) 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
DK2427485T3 (en) 2009-05-07 2017-03-13 Immunocellular Therapeutics Ltd CD133 epitopes
EP2809775B1 (en) * 2012-02-02 2018-06-13 Caladrius Biosciences, Inc. Pluripotent germ layer origin antigen presenting cancer vaccine
JP6134785B2 (ja) 2012-05-31 2017-05-24 ジェイダブリュ クレアジェン インコーポレイテッド 樹状細胞成熟化組成物、およびこれを用いて抗原特異的樹状細胞を製造する方法
AU2020203845C1 (en) * 2012-09-06 2022-08-11 Orbis Health Solutions, Llc Tumor lysate loaded particles
US20140065173A1 (en) 2012-09-06 2014-03-06 Orbis Health Solutions Llc Tumor lysate loaded particles
US10188672B2 (en) 2012-12-12 2019-01-29 Orbis Health Solutions Llc Compositions and methods for tissue regeneration
CA2898474A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
CN112891522A (zh) * 2013-09-05 2021-06-04 奥比思健康解决方案有限责任公司 装载了肿瘤裂解物的微粒
EP3932392A1 (en) 2014-03-05 2022-01-05 Orbis Health Solutions LLC Vaccine delivery systems using yeast cell wall particles
US10599155B1 (en) 2014-05-20 2020-03-24 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation feature monitoring and evaluation of effectiveness
US9972054B1 (en) 2014-05-20 2018-05-15 State Farm Mutual Automobile Insurance Company Accident fault determination for autonomous vehicles
US10185998B1 (en) 2014-05-20 2019-01-22 State Farm Mutual Automobile Insurance Company Accident fault determination for autonomous vehicles
US11669090B2 (en) 2014-05-20 2023-06-06 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation feature monitoring and evaluation of effectiveness
US10373259B1 (en) 2014-05-20 2019-08-06 State Farm Mutual Automobile Insurance Company Fully autonomous vehicle insurance pricing
US9783159B1 (en) 2014-07-21 2017-10-10 State Farm Mutual Automobile Insurance Company Methods of theft prevention or mitigation
US10915965B1 (en) 2014-11-13 2021-02-09 State Farm Mutual Automobile Insurance Company Autonomous vehicle insurance based upon usage
RU2018103235A (ru) * 2015-06-30 2019-07-31 Нортвест Биотерапьютикс, Инк. Оптимально активированные дендритные клетки, индуцирующие улучшенный или повышенный противоопухолевый иммунный ответ
BR112018000027A2 (pt) 2015-06-30 2022-09-06 Univ Nova De Lisboa População celular viável, método de produção e usos da mesma
US9805601B1 (en) 2015-08-28 2017-10-31 State Farm Mutual Automobile Insurance Company Vehicular traffic alerts for avoidance of abnormal traffic conditions
US10395332B1 (en) 2016-01-22 2019-08-27 State Farm Mutual Automobile Insurance Company Coordinated autonomous vehicle automatic area scanning
US11441916B1 (en) 2016-01-22 2022-09-13 State Farm Mutual Automobile Insurance Company Autonomous vehicle trip routing
US10386845B1 (en) 2016-01-22 2019-08-20 State Farm Mutual Automobile Insurance Company Autonomous vehicle parking
US11242051B1 (en) 2016-01-22 2022-02-08 State Farm Mutual Automobile Insurance Company Autonomous vehicle action communications
US10134278B1 (en) 2016-01-22 2018-11-20 State Farm Mutual Automobile Insurance Company Autonomous vehicle application
US10324463B1 (en) 2016-01-22 2019-06-18 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation adjustment based upon route
US11719545B2 (en) 2016-01-22 2023-08-08 Hyundai Motor Company Autonomous vehicle component damage and salvage assessment
KR102038114B1 (ko) * 2016-02-26 2019-10-30 주식회사 엘지화학 광학 점착제용 (메타)아크릴레이트기 함유 벤조페논의 제조방법 및 광학 점착제 조성물
WO2018160666A1 (en) * 2017-02-28 2018-09-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated dc1s and methods for their production and use
MX2022004186A (es) * 2019-10-07 2022-07-19 Northwest Biotherapeutics Inc Composiciones y métodos in vitro para potenciar la activación de células dendríticas y células t, y para inducir una respuesta inmune th-1.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5366866A (en) * 1991-07-25 1994-11-22 Duke University Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB
US5227471A (en) * 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
EA199800272A1 (ru) * 1995-10-04 1998-10-29 Иммунекс Корпорейшн Фактор, стимулирующий дендритные клетки
US7659119B2 (en) * 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
EP2058389B1 (en) * 1997-10-27 2016-05-18 Rockefeller University Defined dendritic cell maturation medium comprising TNF-alpha, IL-1beta, IL-6
JP2000143534A (ja) * 1998-11-13 2000-05-23 Asahi Chem Ind Co Ltd 樹状細胞ワクチン及びその製造方法
JP2000279181A (ja) * 1999-04-01 2000-10-10 Japan Science & Technology Corp ヒト樹状細胞の発現遺伝子群
WO2001048154A1 (fr) * 1999-12-28 2001-07-05 Toyoshima, Kumao Agent de maturation pour cellules dendritiques immatures
US6247378B1 (en) * 2000-01-06 2001-06-19 Deere & Company Operator control device for an infinitely variable transmission
ES2375948T3 (es) * 2000-05-12 2012-03-07 Northwest Biotherapeutics, Inc. Procedimiento para aumentar la presentación de clase i de ant�?genos exógenos por células dendr�?ticas humanas.
EP1352052B1 (en) * 2001-01-15 2006-02-08 I.D.M. Immuno-Designed Molecules Method for preparing submicron particle suspensions of pharmaceutical agents
WO2003010292A2 (en) * 2001-07-25 2003-02-06 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors

Also Published As

Publication number Publication date
WO2003022215A3 (en) 2003-11-13
CA2459713A1 (en) 2003-03-20
CN102973928B (zh) 2019-03-15
CA2459713C (en) 2015-08-18
KR20140116544A (ko) 2014-10-02
CN1636229A (zh) 2005-07-06
JP2015107133A (ja) 2015-06-11
HK1079989A1 (en) 2006-04-21
PT2322603T (pt) 2020-01-21
JP6114768B2 (ja) 2017-04-12
NO20040965L (no) 2004-04-23
WO2003022215A2 (en) 2003-03-20
KR20050027163A (ko) 2005-03-17
DK2322603T3 (da) 2020-01-27
JP2005505270A (ja) 2005-02-24
AU2008221592B2 (en) 2012-12-20
NO20151562A1 (no) 2015-11-16
JP2011188872A (ja) 2011-09-29
BRPI0212545A8 (pt) 2019-10-15
ES2598109T3 (es) 2017-01-25
KR101803702B1 (ko) 2017-12-01
EP3653055A1 (en) 2020-05-20
IL219266A0 (en) 2012-06-28
ES2766299T3 (es) 2020-06-12
EP1441591B1 (en) 2016-06-29
BRPI0212545B1 (pt) 2019-12-03
CN102973928A (zh) 2013-03-20
NO338147B1 (no) 2016-08-01
EP1441591A4 (en) 2006-06-07
PL372098A1 (en) 2005-07-11
EP1441591A2 (en) 2004-08-04
DK1441591T3 (en) 2017-05-22
IL160720A (en) 2012-05-31
PT1441591T (pt) 2016-10-06
CN1636229B (zh) 2012-12-19
AU2008221592A1 (en) 2008-10-16
BRPI0212545B8 (pt) 2021-05-25
IL219266A (en) 2014-02-27
NZ531530A (en) 2007-01-26
EP2322603B1 (en) 2019-10-16
JP5777956B2 (ja) 2015-09-16
US20050059151A1 (en) 2005-03-17
MXPA04002147A (es) 2005-03-07
US20080254064A1 (en) 2008-10-16
EP2322603A1 (en) 2011-05-18
KR20110081341A (ko) 2011-07-13
BR0212545A (pt) 2005-01-18

Similar Documents

Publication Publication Date Title
IL160720A0 (en) Composition and methods for priming monocytic dendritic cells and t cells for th-1 response
AU2003253897A8 (en) Dendritic cell pontentiation
AU2002318944A1 (en) Methods and compositions relating to plasmacytoid dendritic cells
IL159578A (en) Differentiated cell population for generating osteoprogenitors or osteoblasts
AU6778001A (en) Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
AU2002249531A1 (en) Immunotherapy based on dendritic cells
IL151415A0 (en) Electrical cells, components and methods
AU2002367825A8 (en) Graft polymer matrices
AU2003297595A8 (en) Atm kinase compositions and methods
AU2002235728A8 (en) Method for generating insulin-secreting cells suitable for transplantation
EP1420469A4 (en) CELL
AU2003247449A1 (en) Nano-ceramics and method thereof
AU2002305452A1 (en) Regulating immine responses using dendritic cells
GB0217907D0 (en) Polymerisable dicyclohexylbenzenes
GB0103779D0 (en) Fuel cells
AU6229701A (en) Dendritic cells loaded with toxic substances
AU2002365938A8 (en) Modified antigen-presenting cells
AU2001271926A1 (en) Methods for promoting dendritic cell proliferation or differentiation
EP1411897A4 (en) COMPOSITIONS AND METHODS FOR INTRA-CELLULAR DELIVERY
EP1283727A4 (en) COMPOSITIONS AND METHODS FOR INDUCING THE ACTIVATION OF DENDRITIC CELLS
AU2002365136A8 (en) Compositions and methods for controlled release
AU2002336522A1 (en) Compositions and methods for t cell priming and immunotherapy
AU2002315841A1 (en) Magnesium-based alloy
EP1432811A4 (en) CELL SEPARATION MATRIX
AU2002241930A1 (en) Methods and compositions for extracting proteins from cells